▁British 8.59375
▁Bi 8.046875
ote 1.80859375
ch 0.123779296875
' 5.16796875
s 0.0084686279296875
▁Mar 8.125
im 7.58203125
ast 0.64208984375
at 0.00039577484130859375
▁Anti 7.21875
- 0.126708984375
Can 1.8466796875
cer 0.00042438507080078125
▁Tre 3.970703125
at 0.0016317367553710938
ment 0.01543426513671875
: 5.421875
▁A 2.27734375
▁Ray 7.69140625
▁of 0.2325439453125
▁Hope 0.275634765625
▁to 4.59765625
▁be 4.93359375
▁Review 6.6953125
ed 0.003662109375
▁at 2.138671875
▁ES 7.68359375
MO 0.00406646728515625
▁Conference 5.39453125
▁in 1.861328125
▁Vienna 2.52734375
<0x0A> 0.28759765625
VI 8.875
EN 0.12548828125
NA 0.004909515380859375
▁- 4.91015625
▁In 5.109375
▁a 1.6923828125
▁significant 3.607421875
▁development 0.88623046875
▁for 1.1494140625
▁the 1.1806640625
▁field 3.15625
▁of 0.035186767578125
▁on 0.83447265625
col 0.0233306884765625
ogy 9.620189666748047e-05
, 0.1888427734375
▁British 1.4833984375
▁ph 4.38671875
arma 0.004505157470703125
ce 0.029937744140625
ut 7.867813110351562e-05
ical 0.0006060600280761719
▁company 0.353271484375
▁British 3.76953125
▁Bi 0.0194854736328125
ote 0.0020236968994140625
ch 0.0043792724609375
▁announced 3.251953125
▁that 1.4091796875
▁its 1.4453125
▁break 5.8125
through 0.01346588134765625
▁anti 1.02734375
- 0.004245758056640625
can 0.03472900390625
cer 0.00026297569274902344
▁treatment 0.6728515625
, 0.826171875
▁Mar 0.9306640625
im 0.002490997314453125
ast 0.00018846988677978516
at 2.2411346435546875e-05
, 0.2186279296875
▁will 0.3798828125
▁be 0.061279296875
▁closely 8.6328125
▁exam 1.59375
ined 0.0004801750183105469
▁at 0.560546875
▁the 0.312255859375
▁up 2.009765625
coming 0.0106201171875
▁European 0.66357421875
▁Society 0.10760498046875
▁for 0.140380859375
▁Medical 0.003017425537109375
▁On 0.004306793212890625
col 0.00627899169921875
ogy 8.45193862915039e-05
▁( 0.17333984375
ES 0.00476837158203125
MO 0.00033092498779296875
) 0.0187225341796875
▁conference 0.88134765625
▁in 0.375732421875
▁Vienna 0.0221710205078125
. 0.83935546875
▁With 4.06640625
▁exper 4.85546875
ts 0.00084686279296875
▁from 0.662109375
▁around 0.63671875
▁the 0.015777587890625
▁world 0.1435546875
▁gather 1.1875
ing 0.0005764961242675781
▁to 0.197998046875
▁discuss 0.425537109375
▁the 0.3369140625
▁latest 0.05706787109375
▁adv 0.5107421875
anc 0.78271484375
ements 0.0022373199462890625
▁in 0.0487060546875
▁on 1.92578125
col 0.0292205810546875
ogy 1.8358230590820312e-05
▁research 1.865234375
, 0.5390625
▁this 1.1591796875
▁review 3.4140625
▁holds 5.08984375
▁promise 5.35546875
▁for 0.25732421875
▁the 1.9541015625
▁future 0.297607421875
▁of 0.044769287109375
▁cancer 0.280029296875
▁treatment 0.2269287109375
. 0.443359375
<0x0A> 0.1026611328125
Mar 1.33984375
im 0.0028018951416015625
ast 0.0001245737075805664
at 0.0002770423889160156
, 1.2685546875
▁a 0.91357421875
▁novel 2.2578125
▁bi 4.01171875
ote 3.724609375
chn 0.49853515625
ology 0.1529541015625
▁drug 1.8017578125
, 0.78173828125
▁has 0.83984375
▁shown 1.3525390625
▁great 2.068359375
▁potential 0.75390625
▁in 0.25
▁advanced 7.9453125
▁cancer 1.455078125
▁patients 1.2607421875
, 1.5537109375
▁particularly 1.939453125
▁those 0.4033203125
▁suffering 1.9755859375
▁from 0.00516510009765625
▁met 2.89453125
ast 0.002246856689453125
atic 0.052764892578125
▁can 3.552734375
cers 0.0001456737518310547
. 0.576171875
▁British 4.953125
▁Bi 0.00994873046875
ote 0.00011229515075683594
ch 0.00327301025390625
' 1.0
s 0.00011682510375976562
▁research 2.12890625
▁and 2.88671875
▁development 0.29443359375
▁team 0.85205078125
▁has 0.90576171875
▁conducted 2.865234375
▁extensive 0.5048828125
▁pre 3.537109375
cl 0.57470703125
in 6.198883056640625e-05
ical 0.0002956390380859375
▁tri 2.712890625
als 2.3245811462402344e-05
▁and 1.2421875
▁clin 1.177734375
ical 0.0004284381866455078
▁studies 0.4306640625
, 1.3427734375
▁which 1.9853515625
▁have 0.27978515625
▁yield 1.84765625
ed 2.872943878173828e-05
▁prom 0.93310546875
ising 3.612041473388672e-05
▁results 0.042999267578125
. 0.2481689453125
▁As 4.890625
▁a 0.490234375
▁result 0.60400390625
, 0.0791015625
▁the 0.69970703125
▁ES 3.46875
MO 0.0003368854522705078
▁panel 4.13671875
▁has 1.5390625
▁recognized 3.0625
▁the 0.6767578125
▁need 2.154296875
▁to 1.1064453125
▁evaluate 2.373046875
▁the 1.0302734375
▁treatment 2.181640625
' 0.92822265625
s 6.16312026977539e-05
▁effic 1.3330078125
acy 2.2172927856445312e-05
▁and 0.40478515625
▁potential 2.603515625
▁impact 2.50390625
▁on 0.1075439453125
▁patient 1.16015625
▁out 0.2705078125
comes 4.589557647705078e-05
. 0.10870361328125
<0x0A> 0.04132080078125
The 0.828125
▁drug 5.875
▁focus 8.1328125
es 0.0029850006103515625
▁on 0.0340576171875
▁in 2.0
hib 0.0044403076171875
iting 0.0124969482421875
▁a 2.025390625
▁specific 1.16796875
▁en 0.478271484375
zym 2.6702880859375e-05
e 0.004268646240234375
, 0.95947265625
▁matrix 1.04296875
▁metal 0.00649261474609375
lo 0.0009655952453613281
prote 0.0219879150390625
in 0.024871826171875
ases 2.169921875
▁( 0.206298828125
M 0.00720977783203125
MP 0.00010216236114501953
s 0.1085205078125
), 0.0870361328125
▁which 0.265869140625
▁plays 2.75390625
▁a 0.1478271484375
▁cru 1.0263671875
cial 2.4557113647460938e-05
▁role 0.001178741455078125
▁in 0.00019466876983642578
▁tum 1.9033203125
or 0.11956787109375
▁growth 0.8544921875
▁and 0.258544921875
▁met 0.69482421875
ast 0.0013570785522460938
asis 0.0303955078125
. 0.03125
▁By 0.267822265625
▁cont 6.7890625
rolling 4.8279762268066406e-05
▁the 0.87353515625
▁activity 0.4111328125
▁of 0.0031223297119140625
▁these 1.751953125
▁en 0.06903076171875
zym 2.0265579223632812e-06
es 0.00021457672119140625
, 0.01242828369140625
▁Mar 0.1080322265625
im 0.0009832382202148438
ast 0.0001270771026611328
at 0.00015604496002197266
▁may 3.546875
▁h 8.1953125
inder 0.0005826950073242188
▁cancer 1.740234375
▁cell 1.0283203125
▁invasion 2.27734375
▁and 0.268798828125
▁decrease 6.41796875
▁the 0.86083984375
▁pro 4.5546875
l 1.5078125
ifer 6.556510925292969e-06
ation 0.0066680908203125
▁of 0.0726318359375
▁tum 0.7490234375
ors 0.92333984375
. 0.1690673828125
▁Research 6.02734375
ers 1.0341796875
▁believe 1.2373046875
▁this 2.798828125
▁target 4.38671875
ed 0.07623291015625
▁approach 0.2005615234375
▁could 1.0146484375
▁provide 2.3203125
▁a 0.49658203125
▁more 1.1552734375
▁effective 0.2568359375
▁alternative 4.15625
▁to 0.0232391357421875
▁conventional 1.630859375
▁cancer 1.6181640625
▁treat 0.447265625
ments 6.079673767089844e-06
, 0.55712890625
▁such 1.52734375
▁as 3.147125244140625e-05
▁chem 0.0482177734375
other 0.0019512176513671875
apy 0.0003123283386230469
. 2.3515625
<0x0A> 0.01163482666015625
The 1.234375
▁ES 0.61572265625
MO 9.66787338256836e-05
▁conference 0.7939453125
, 1.595703125
▁held 2.970703125
▁ann 1.689453125
ually 1.5974044799804688e-05
, 0.79541015625
▁is 1.0458984375
▁known 3.849609375
▁for 0.23046875
▁bringing 2.43359375
▁together 0.0223388671875
▁exper 1.5830078125
ts 2.86102294921875e-06
, 4.484375
▁top 7.74609375
▁research 1.474609375
ers 0.0202789306640625
, 0.07244873046875
▁and 0.1480712890625
▁health 2.6484375
care 0.15283203125
▁profession 0.1754150390625
als 1.9073486328125e-06
▁in 2.6953125
▁the 0.1995849609375
▁field 0.207763671875
▁of 0.04669189453125
▁on 0.07196044921875
col 0.0012063980102539062
ogy 1.3113021850585938e-06
. 0.19775390625
▁It 2.84375
▁serves 2.22265625
▁as 0.004734039306640625
▁a 0.306884765625
▁platform 0.2666015625
▁for 0.11224365234375
▁sharing 1.6923828125
▁ground 3.80078125
bre 0.0989990234375
aking 1.1920928955078125e-06
▁research 1.1103515625
, 1.66796875
▁fost 4.05859375
ering 0.000579833984375
▁collaboration 0.7216796875
, 0.126220703125
▁and 0.004489898681640625
▁en 4.6640625
han 0.300537109375
cing 3.6954879760742188e-06
▁the 1.482421875
▁understanding 2.109375
▁of 0.053680419921875
▁cancer 0.428466796875
▁bi 2.064453125
ology 0.003223419189453125
▁and 0.400146484375
▁ther 2.35546875
apy 0.64794921875
. 0.034820556640625
<0x0A> 0.73583984375
D 4.3671875
uring 0.12298583984375
▁the 0.1097412109375
▁conference 0.56787109375
, 0.0171661376953125
▁British 1.044921875
▁Bi 0.0027790069580078125
ote 3.4332275390625e-05
ch 0.0005664825439453125
▁is 3.232421875
▁scheduled 1.66796875
▁to 0.0061798095703125
▁present 0.3818359375
▁clin 5.3515625
ical 0.003086090087890625
▁trial 2.501953125
▁data 0.798828125
▁that 2.646484375
▁demonstr 2.984375
ates 8.499622344970703e-05
▁Mar 1.146484375
im 0.001129150390625
ast 0.0004203319549560547
at 0.00021576881408691406
' 0.0157928466796875
s 0.00020039081573486328
▁initial 9.6640625
▁success 2.62890625
▁in 0.23193359375
▁patients 2.232421875
▁with 0.233154296875
▁various 3.08984375
▁forms 2.361328125
▁of 0.0008730888366699219
▁cancer 0.58154296875
, 1.0078125
▁including 0.11370849609375
▁breast 1.693359375
, 0.28955078125
▁lung 1.3837890625
, 0.00579833984375
▁and 0.6142578125
▁pan 2.294921875
cre 9.334087371826172e-05
atic 0.08917236328125
▁can 1.2880859375
cers 4.279613494873047e-05
. 0.0261383056640625
▁Pre 6.50390625
lim 0.458984375
inary 0.00013196468353271484
▁find 1.2177734375
ings 2.2649765014648438e-06
▁suggest 1.1484375
▁that 0.0745849609375
▁Mar 2.421875
im 0.0006723403930664062
ast 3.5762786865234375e-05
at 0.00026607513427734375
▁not 5.5546875
▁only 0.00478363037109375
▁exhib 5.31640625
its 0.07586669921875
▁anti 1.65625
- 0.0019664764404296875
t 0.74951171875
um 6.330013275146484e-05
oral 3.90234375
▁benefits 7.07421875
▁but 0.29248046875
▁also 0.26025390625
▁ass 7.9375
ists 0.033721923828125
▁in 0.3671875
▁reducing 1.66796875
▁cancer 3.5703125
- 0.50927734375
associ 1.5732421875
ated 0.00037097930908203125
▁sympt 1.9716796875
oms 0.011962890625
, 0.904296875
▁impro 3.46484375
ving 0.0244140625
▁patients 1.4892578125
' 0.005420684814453125
▁quality 0.195068359375
▁of 0.00078582763671875
▁life 0.00043511390686035156
. 0.1929931640625
<0x0A> 0.10711669921875
Comment 6.22265625
ing 0.007755279541015625
▁on 0.0032501220703125
▁the 0.150390625
▁significance 1.22265625
▁of 0.004016876220703125
▁show 9.0234375
c 0.004123687744140625
asing 9.191036224365234e-05
▁Mar 0.703125
im 0.0012960433959960938
ast 0.00020194053649902344
at 0.00028777122497558594
▁at 0.30078125
▁the 0.2958984375
▁ES 0.6083984375
MO 0.00010895729064941406
▁conference 0.130126953125
, 0.0443115234375
▁Dr 1.4326171875
. 0.051239013671875
▁Am 5.6640625
anda 1.962890625
▁Rod 7.28515625
rig 0.98291015625
uez 0.83349609375
, 0.196044921875
▁Chief 1.8623046875
▁Medical 0.417236328125
▁Officer 0.0279083251953125
▁at 0.64892578125
▁British 0.01287078857421875
▁Bi 0.00231170654296875
ote 3.361701965332031e-05
ch 0.0014810562133789062
, 0.049591064453125
▁stated 0.82177734375
, 0.432373046875
▁" 0.03179931640625
We 0.66357421875
▁are 0.1456298828125
▁thr 0.98095703125
illed 3.0994415283203125e-06
▁to 0.08575439453125
▁have 1.009765625
▁the 0.2734375
▁opportunity 0.022735595703125
▁to 0.0016269683837890625
▁present 0.53564453125
▁our 0.33642578125
▁research 2.498046875
▁find 1.966796875
ings 1.3113021850585938e-06
▁on 2.615234375
▁Mar 0.1893310546875
im 0.0003666877746582031
ast 0.00010502338409423828
at 9.012222290039062e-05
▁at 0.80322265625
▁such 1.73828125
▁a 0.14404296875
▁pr 0.1163330078125
estig 1.6689300537109375e-06
ious 1.537799835205078e-05
▁event 0.43310546875
. 0.2325439453125
▁This 1.1513671875
▁validation 5.97265625
▁from 1.236328125
▁the 0.8857421875
▁scientific 3.4453125
▁community 0.095703125
▁further 3.3046875
▁motiv 4.015625
ates 0.0007119178771972656
▁us 0.425537109375
▁to 0.04473876953125
▁continue 0.40576171875
▁our 0.446044921875
▁purs 3.703125
uit 0.0071868896484375
▁of 0.0921630859375
▁impro 2.509765625
ving 2.086162567138672e-05
▁cancer 1.3798828125
▁treatment 1.015625
▁options 1.412109375
▁and 2.064453125
▁patients 6.5390625
' 0.0103302001953125
▁lives 1.091796875
." 0.245361328125
<0x0A> 0.013824462890625
Wh 4.09375
ile 0.0008516311645507812
▁the 0.92626953125
▁road 6.23046875
▁to 0.28369140625
▁regul 5.5546875
atory 0.00010335445404052734
▁appro 0.00891876220703125
val 2.276897430419922e-05
▁and 1.9755859375
▁w 1.3544921875
ides 1.9311904907226562e-05
p 0.00032138824462890625
read 1.8477439880371094e-05
▁avail 2.103515625
ability 8.7738037109375e-05
▁is 3.025390625
▁still 0.552734375
▁long 0.97021484375
, 0.1341552734375
▁the 0.90185546875
▁high 8.375
- 1.560546875
profile 0.951171875
▁show 4.2578125
case 0.225830078125
▁at 1.0185546875
▁ES 0.810546875
MO 3.719329833984375e-05
▁provides 2.333984375
▁British 2.4375
▁Bi 0.0013427734375
ote 1.6689300537109375e-05
ch 0.00024020671844482422
▁with 0.1302490234375
▁a 0.88671875
▁unique 1.7705078125
▁opportunity 0.5234375
▁to 0.014617919921875
▁eng 3.13671875
age 7.784366607666016e-05
▁with 0.168212890625
▁leading 2.390625
▁on 1.2158203125
colog 0.9453125
ists 0.0037670135498046875
, 1.39453125
▁research 1.755859375
ers 0.0126953125
, 0.0036334991455078125
▁and 0.0233306884765625
▁decision 3.544921875
- 0.028961181640625
m 0.00074005126953125
akers 3.4570693969726562e-06
▁in 0.9697265625
▁the 0.047698974609375
▁field 0.43115234375
▁of 2.48828125
▁cancer 0.7421875
▁th 4.51171875
era 0.0001068115234375
pe 0.00018405914306640625
ut 6.306171417236328e-05
ics 0.00319671630859375
. 0.01654052734375
▁This 2.37109375
▁event 2.796875
▁could 2.4609375
▁potentially 1.9345703125
▁lead 2.12890625
▁to 0.0014963150024414062
▁prom 4.84375
ising 0.00257110595703125
▁collabor 0.8515625
ations 0.03753662109375
, 1.33203125
▁thereby 8.1953125
▁exp 5.46875
edit 5.1975250244140625e-05
ing 0.0018091201782226562
▁the 0.17333984375
▁path 4.68359375
▁of 4.671875
▁Mar 0.90576171875
im 0.00164031982421875
ast 0.00023245811462402344
at 0.00020456314086914062
▁towards 2.3359375
▁clin 1.814453125
ical 0.0035419464111328125
▁application 2.3828125
. 0.409912109375
<0x0A> 0.08441162109375
The 2.0546875
▁ES 0.9345703125
MO 9.59634780883789e-05
▁conference 0.1844482421875
, 1.6318359375
▁taking 2.0
▁place 0.0003285408020019531
▁from 0.744140625
▁September 0.322509765625
▁ 0.0009617805480957031
1 2.583984375
8 2.8671875
- 1.021484375
2 0.02783203125
2 2.19921875
, 0.222412109375
▁will 2.2265625
▁see 4.3359375
▁over 1.9814453125
▁ 0.01031494140625
2 0.849609375
5 1.4677734375
, 0.046600341796875
0 0.0022258758544921875
0 2.586841583251953e-05
0 0.00019729137420654297
▁research 4.94921875
ers 0.0204315185546875
, 0.5791015625
▁clin 1.2783203125
icians 0.03961181640625
, 0.01219940185546875
▁and 0.19677734375
▁industry 2.189453125
▁exper 2.28125
ts 2.6226043701171875e-06
▁coming 4.48828125
▁together 0.00850677490234375
▁to 0.265869140625
▁discuss 1.08984375
▁the 0.64208984375
▁latest 0.0946044921875
▁adv 0.89404296875
anc 0.289306640625
ements 2.8133392333984375e-05
▁in 0.18896484375
▁on 0.654296875
col 0.0165863037109375
ogy 3.0994415283203125e-06
▁research 1.53515625
▁and 1.1474609375
▁treatment 1.009765625
▁strateg 4.1328125
ies 7.152557373046875e-06
. 0.019134521484375
▁A 5.8828125
part 1.5107421875
▁from 7.43865966796875e-05
▁Mar 1.212890625
im 0.0008449554443359375
ast 0.00023806095123291016
at 0.000179290771484375
, 0.09295654296875
▁numerous 2.6015625
▁other 0.1810302734375
▁ground 2.7421875
bre 0.1964111328125
aking 6.079673767089844e-06
▁ther 1.9873046875
ap 0.0015048980712890625
ies 2.9802322387695312e-05
▁and 0.947265625
▁novel 3.55078125
▁approaches 1.310546875
▁will 1.181640625
▁be 0.1873779296875
▁expl 4.0390625
ored 6.902217864990234e-05
▁during 1.521484375
▁the 0.2060546875
▁event 1.0068359375
. 0.375732421875
<0x0A> 0.1810302734375
As 2.291015625
▁the 0.9189453125
▁conference 3.3671875
▁approaches 1.3076171875
, 0.01036834716796875
▁the 1.6796875
▁anticip 2.375
ation 0.005069732666015625
▁surrounding 2.05859375
▁British 2.29296875
▁Bi 0.00139617919921875
ote 4.0650367736816406e-05
ch 0.0005745887756347656
' 0.038360595703125
s 8.463859558105469e-05
▁Mar 1.4677734375
im 0.0005774497985839844
ast 7.987022399902344e-05
at 8.535385131835938e-05
▁continues 2.302734375
▁to 0.0009851455688476562
▁build 1.3681640625
. 0.368408203125
▁The 1.1044921875
▁spot 7.921875
light 9.775161743164062e-05
▁will 4.51171875
▁shift 5.828125
▁to 0.71142578125
▁Vienna 0.9599609375
, 0.42431640625
▁where 0.2271728515625
▁this 3.185546875
▁potentially 2.7578125
▁ground 4.0078125
bre 0.1217041015625
aking 2.9802322387695312e-06
▁anti 2.705078125
- 7.402896881103516e-05
can 0.0083465576171875
cer 2.086162567138672e-05
▁treatment 0.269775390625
▁will 0.1961669921875
▁be 0.2108154296875
▁exam 3.310546875
ined 3.421306610107422e-05
, 3.771484375
▁evaluated 1.2294921875
, 0.01934814453125
▁and 0.00244140625
▁potentially 3.009765625
▁p 3.6953125
ave 0.2471923828125
▁the 0.017486572265625
▁way 0.0164794921875
▁for 0.1451416015625
▁new 2.634765625
▁v 10.625
istas 0.041595458984375
▁in 0.11932373046875
▁the 1.4658203125
▁fight 1.4697265625
▁against 0.0007100105285644531
▁cancer 0.1103515625
. 0.01203155517578125
